222 results on '"Houben, E."'
Search Results
52. PCV3 - No Evidence For An Association Between Renal Function And Bleeding Events In Patients On Coumarin Therapy: A Population-Based Study
- Author
-
Houben, E, Smits, E, Overbeek, JA, Herings, RM, Van Herk-Sukel, MP, Teichert, M, and de Smet, PA
- Published
- 2017
- Full Text
- View/download PDF
53. PIH31 - Medication Use During Pregnancy in the Netherlands: A Population-Based Study
- Author
-
Houben, E, Bezemer, I, Hukkelhoven, C, Steegers, E, and Herings, R
- Published
- 2017
- Full Text
- View/download PDF
54. PUK24 - Potential Medication Triggers Of Deteriorated Renal Function Among Patients With Type 2 Diabetes: Using Real World Data
- Author
-
Smits, E, Houben, E, Overbeek, JA, de Smet, PA, van Herk-Sukel, MP, Herings, RM, and Teichert, M
- Published
- 2017
- Full Text
- View/download PDF
55. PRM57 - Linkage Of The Pharmo Database Network And The Netherlands Perinatal Registry To Construct A Cohort That Captures Pregnancy And Postnatal Outcomes
- Author
-
Houben, E, Bezemer, ID, and Herings, RM
- Published
- 2016
- Full Text
- View/download PDF
56. Groundwater: hidden treasure or Pandora’s box? A case study on resistant bacteria in the drink watersupply at Oasen, Gouda: an interdisciplinary approach
- Author
-
Houben, E., van der Lecq, R. (Thesis Advisor), Houben, E., and van der Lecq, R. (Thesis Advisor)
- Abstract
As increasing evidence of the march of the antimicrobial resistant bacteria increased awareness, governments and health agencies have started investigations on how to minimize risks for public health. These studies revealed the large-scale usage of antibiotics and its effects on water-collection areas. In this study, we will try to provide a broader and more comprehensive answer to the question to what extent resistant bacteria in the aquatic system pose a threat to public health by contaminating potable water in water-collection areas. We will focus on one particular water treatment plant, namely Oasen in Gouda. Therefore, this study is focussed on one single aquatic system. Furthermore, we will narrow the public health component to the most harmful bacteria for the civil community receiving their potable water from Oasen.
- Published
- 2012
57. Analysis of the urinary glucose-[¹⁵N, ¹⁵N]-ureide content in the study of the lactose-[¹⁵N, ¹⁵N]-ureide metabolism in healthy humans.
- Author
-
De Preter V, Houben E, Windey K, Luypaerts A, Verbeke K, De Preter, V, Houben, E, Windey, K, Luypaerts, A, and Verbeke, K
- Abstract
Background/objectives: Lactose-[(15)N, (15)N]-ureide is used to study the fate of the colonic urea-nitrogen metabolism. During the passage through the gastrointestinal tract, lactose ureide is hydrolysed to glucose ureide, which is absorbed to a limited extent from the small intestine and is excreted urinarily. In the present study, a procedure has been developed to quantify the urinary excretion of glucose-[(15)N, (15)N]-ureide. In addition, urine and faecal samples obtained during a dietary intervention study with the prebiotic lactulose were retrospectively analysed.Subjects/methods: The glucose ureide and lactose ureide content was measured by GC-MS in 19 healthy volunteers. After consumption of a standard test meal containing 75 mg lactose-[(15)N, (15)N]-ureide, six healthy volunteers performed a fractionated 24 h urine collection to investigate the urinary excretion of glucose-[(15)N, (15)N]-ureide. In 13 volunteers, the effect of lactulose administration on the urinary excretion of glucose-[(15)N, (15)N]-ureide was analysed.Results: The urinary excretion of glucose-[(15)N, (15)N]-ureide reached its maximum level in the 3-6 h urine collection and decreased in the 6-9 h urine. The label was still detectable in the 9-24 h urine collection. The cumulative excretion of (15)N-labelled glucose ureide after 24 h amounted 12.91%. No significant differences in glucose-[(15)N, (15)N]-ureide excretion were found in either of the urine fractions after administration of lactulose, compared with baseline. In none of the urine samples lactose-[(15)N, (15)N]-ureide was detected.Conclusions: In conclusion, the results obtained in the present study indicated that the percentage dose glucose-[(15)N, (15)N]-ureide recovered in urine is rather constant and not influenced by the presence of lactulose. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
58. Kinetic characteristics of acidic and alkaline ceramidase in human epidermis
- Author
-
Houben, E., Uchida, Y., Nieuwenhuizen, W.F., Paepe, K. de, Vanhaecke, T., Holleran, W.M., Rogiers, V., Houben, E., Uchida, Y., Nieuwenhuizen, W.F., Paepe, K. de, Vanhaecke, T., Holleran, W.M., and Rogiers, V.
- Abstract
It has recently become evident that at least five ceramidase (CDase) isoforms are present in human epidermis, and that specifically acidic CDase (aCDase) and alkaline CDase (alkCDase) activities increase during keratinocyte differentiation, and thus might play a pivotal role(s) in permeability barrier function. Prior to investigating their possible roles in the epidermal barrier function, it is necessary to characterize basic kinetic parameters for these enzymes, as well as to determine the effects of the established CDase inhibitors and their activities. In this study, assays for both aCDase and alkCDase activities in fully differentiated human epidermis were optimized using a radiolabeled substrate. These studies revealed that aCDase activity is substantially higher than alkCDase activity, and that both isoenzymes are inhibited by a CDase inhibitor N-oleylethanolamine. These findings were also confirmed using an in situ enzyme assay. Copyright © 2007 S. Karger AG.
- Published
- 2007
59. PCV31 - Clinical Characteristics, Lipid Treatment and Goal Attainment in a Familial Hypercholesterolemia Cohort in The Netherlands: a Cross Sectional Study
- Author
-
Kuiper, JG, Heintjes, EM, Houben, E, Penning-van Beest, FJ, Sanchez, RJ, Khan, I, van Riemsdijk, M, Hovingh, GK, and Herings, RM
- Published
- 2015
- Full Text
- View/download PDF
60. Interplay of signal recognition particle and trigger factor at L23 near the nascent chain exit site on the Escherichia coli ribosome
- Author
-
Ullers, R S, Houben, E N G, Raine, A, ten Hagen-Jongman, C M, Ehrenberg, M, Brunner, J, Oudega, B, Harms, N, Luirink, J, Ullers, R S, Houben, E N G, Raine, A, ten Hagen-Jongman, C M, Ehrenberg, M, Brunner, J, Oudega, B, Harms, N, and Luirink, J
- Published
- 2003
61. Seasonal Effects on the Nasolabial Skin Condition
- Author
-
De Paepe, K., primary, Houben, E., additional, Adam, R., additional, Hachem, J.-P., additional, Roseeuw, D., additional, and Rogiers, V., additional
- Published
- 2008
- Full Text
- View/download PDF
62. Epidermal Ceramidase Activity Regulates Epidermal Desquamation via Stratum Corneum Acidification
- Author
-
Houben, E., primary, Hachem, J.P., additional, De Paepe, K., additional, and Rogiers, V., additional
- Published
- 2008
- Full Text
- View/download PDF
63. Effect of dietary intervention with different pre- and probiotics on intestinal bacterial enzyme activities
- Author
-
De Preter, V, primary, Raemen, H, additional, Cloetens, L, additional, Houben, E, additional, Rutgeerts, P, additional, and Verbeke, K, additional
- Published
- 2007
- Full Text
- View/download PDF
64. A Keratinocyte’s Course of Life
- Author
-
Houben, E., primary, De Paepe, K., additional, and Rogiers, V., additional
- Published
- 2006
- Full Text
- View/download PDF
65. PCN232 - Treatment Patterns And Outcomes Of Patients Diagnosed With Ovarian Cancer In The Netherlands: A Registry Study
- Author
-
Houben, E., van Haalen, H.G.M., Sparreboom, W., Overbeek, J.A., Ezendam, N., Pijnenborg, H., and van Herk-Sukel, M.P.P.
- Published
- 2014
- Full Text
- View/download PDF
66. Analysis of Epidermal Lipids of the Healthy Human Skin: Factors Affecting the Design of a Control Population
- Author
-
De Paepe, K., primary, Weerheim, A., additional, Houben, E., additional, Roseeuw, D., additional, Ponec, M., additional, and Rogiers, V., additional
- Published
- 2003
- Full Text
- View/download PDF
67. Analysis of the urinary glucose-[15N, 15N]-ureide content in the study of the lactose-[15N, 15N]-ureide metabolism in healthy humans.
- Author
-
De Preter, V, Houben, E, Windey, K, Luypaerts, A, and Verbeke, K
- Subjects
- *
URINALYSIS , *LACTOSE , *GASTROINTESTINAL system , *DIETARY supplements , *EXCRETION , *DIET therapy , *DRUG administration - Abstract
Background/Objectives:Lactose-[15N, 15N]-ureide is used to study the fate of the colonic urea-nitrogen metabolism. During the passage through the gastrointestinal tract, lactose ureide is hydrolysed to glucose ureide, which is absorbed to a limited extent from the small intestine and is excreted urinarily. In the present study, a procedure has been developed to quantify the urinary excretion of glucose-[15N, 15N]-ureide. In addition, urine and faecal samples obtained during a dietary intervention study with the prebiotic lactulose were retrospectively analysed.Subjects/Methods:The glucose ureide and lactose ureide content was measured by GC-MS in 19 healthy volunteers. After consumption of a standard test meal containing 75 mg lactose-[15N, 15N]-ureide, six healthy volunteers performed a fractionated 24 h urine collection to investigate the urinary excretion of glucose-[15N, 15N]-ureide. In 13 volunteers, the effect of lactulose administration on the urinary excretion of glucose-[15N, 15N]-ureide was analysed.Results:The urinary excretion of glucose-[15N, 15N]-ureide reached its maximum level in the 3-6 h urine collection and decreased in the 6-9 h urine. The label was still detectable in the 9-24 h urine collection. The cumulative excretion of 15N-labelled glucose ureide after 24 h amounted 12.91%. No significant differences in glucose-[15N, 15N]-ureide excretion were found in either of the urine fractions after administration of lactulose, compared with baseline. In none of the urine samples lactose-[15N, 15N]-ureide was detected.Conclusions:In conclusion, the results obtained in the present study indicated that the percentage dose glucose-[15N, 15N]-ureide recovered in urine is rather constant and not influenced by the presence of lactulose. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
68. Real-Time Infrared Determination of Photoinitiated Copolymerization Reactivity Ratios: Application of the Hilbert Transform and Critical Evaluation of Data Analysis Techniques
- Author
-
Jansen, J. F. G. A., Houben, E. E. J. E., Tummers, P. H. G., Wienke, D., and Hoffmann, J.
- Abstract
The reactivity ratios of various UV-copolymerizing systems were determined employing RT-FTIR spectroscopy, combined with advanced and alternative multivariate-statistical data analysis techniques. For complex mixtures peak identification as well as peak deconvolution has been increased significantly by employment of 2-dimensional correlation spectroscopy, based on the Hilbert transform. As an advantage, kinetic reaction profiles of homo- and copolymerization reactions have been extracted and have been separated without any additional measurement. The following reactivity ratios were obtained: fumarate/vinyl ether r
1 = 0, r2 = 0; maleate/vinyl ether r1 = 0, r2 = 0; fumarate/allyl ether r1 = 0, r2 = 0; maleate/allyl ether r1 = 0, r2 = 0; fumarate/methacrylate r1 = 0, r2 = 1.3; fumarate/acrylate r1 = 0, r2 > 50; methacrylate/vinyl ether r1 = 16, r2 = 0; methacrylate/allyl ether r1 > 100, r2 = 0; methacrylate/acrylate r1 = 1.6, r2 = 0.15; methacrylate/N-vinylcaprolactam r1 = 7.3, r2 = 0.01; and acrylate/N-vinylcaprolactam r1 = 1.3, r2 = 0.01. Kinetically, the fumarate−vinyl ether copolymerization can be regarded as the homopolymerization of a CT complex while the fumarate allyl ether copolymerization should be regarded as a perfect alternating copolymerization. The HEA−NVC copolymerization has to be regarded as a terpolymerization between HEA, NVC, and the HEA−NVC charge-transfer complex.- Published
- 2004
69. Nascent Lep inserts into the Escherichia coli inner membrane in the vicinity of YidC, SecY and SecA
- Author
-
Houben, E. N., Scotti, P. A., Valent, Q. A., Brunner, J., Gier, J. W. de, Oudega, B., and Luirink, J.
- Published
- 2000
- Full Text
- View/download PDF
70. PDB113 - Intensification of Basal Insulin Treatment Among Patients With Diabetes Mellitus Type 2 In The Netherlands
- Author
-
Overbeek, J, Houben, E, Kring, S, Sommer, J, Penning-van Beest, F, van der Heijden, A, Nijpels, G, and Herings, R
- Published
- 2015
- Full Text
- View/download PDF
71. Effective protection of the nasolabial skin by using lotion-impregnated paper handkerchiefs during an acute viral cold
- Author
-
Kristien De Paepe, Houben, E., Adam, R., Vera Rogiers, and Toxicology, Dermato-cosmetology and Pharmacognosy
- Abstract
/
72. L’influenza del fosforo, del calcio e del magnesio sulla proteina Gla di matrice e sul processo di calcificazione vascolare: una review sistematica
- Author
-
Houben E., Neradova, A., Leon Schurgers, Marc Vervloet, Biochemie, and RS: CARIM - R1.02 - Vascular aspects thrombosis and haemostasis
73. Nitric oxide is a signal for NNR mediated transcription activation in Paracoccus denitrificans
- Author
-
Spanning, R. J. M., Houben, E., Reijnders, W. N. M., Spiro, S., Hans Westerhoff, Saunders, N. F. W., Systems Bioinformatics, AIMMS, Molecular Microbiology, and Molecular Cell Physiology
- Subjects
Iron-Sulfur Proteins ,Transcriptional Activation ,Nitrates ,Escherichia coli Proteins ,Research Support, Non-U.S. Gov't ,Bacterial ,Gene Expression Regulation, Bacterial ,Research Support ,Nitric Oxide ,Nitrate Reductase ,Promoter Regions ,DNA-Binding Proteins ,Gene Expression Regulation ,Genetic ,Bacterial Proteins ,Nitrate Reductases ,Journal Article ,Non-U.S. Gov't ,Promoter Regions, Genetic ,Paracoccus denitrificans ,Signal Transduction ,Transcription Factors - Abstract
By using the 'lacZ gene, the activities of the nirI, nirS, and norC promoters were assayed in the wild type and in NNR-deficient mutants of Paracoccus denitrificans grown under various growth conditions. In addition, induction profiles of the three promoters in response to the presence of various nitrogenous oxides were determined. Transcription from the three promoters required the absence of oxygen and the presence both of the transcriptional activator NNR and of nitric oxide. The activity of the nnr promoter itself was halved after the cells had been switched from aerobic respiration to denitrification. This response was apparently not a result of autoregulation or of regulation by FnrP, since the nnr promoter was as active in the wild-type strain as it was in NNR- or FnrP-deficient mutants.
74. The influence of phosphate, calcium and magnesium on matrix Gla-protein and vascular calcification: a systematic review
- Author
-
Houben, E., Neradova, A., Leon Schurgers, and Vervloet, M.
- Subjects
nutritional and metabolic diseases - Abstract
Vitamin K-dependent matrix Gla protein (MGP) is a key inhibitor of vascular calcification (VC). MGP is synthesized by chondrocytes and vascular smooth muscle cells (VSMC) and the absence or inactivity of MGP results in excessive calcification of both growth plate and vasculature. Apart from its vitamin K dependency little is known about other factors that influence MGP metabolism. Phosphate, calcium and magnesium are involved in bone mineralization and play an important role in VC. In this review we provide a summary of the effect of phosphate, calcium, and magnesium on MGP metabolism. Elevated phosphate and calcium levels promote VC, in part by increasing the release of matrix vesicles (MV) that under the influence of calcium and phosphate become calcification competent. Phosphate and calcium simultaneously induce an upregulation of MGP protein and gene expression, which possibly inhibits calcification. Elevated phosphate levels did not change MGP protein levels in MV. On the contrary, elevated calcium concentrations caused a decrease of MGPloading in MV, which might in part explainthe calcifying effects of MV. Magnesium is a known inhibitor of VC. However, magnesium has been shown to have an inhibitory effect on MGP synthesis induced through downregulation of the calcium-sensing receptor and hereby causing a decrease in calcium induced MGP upregulation. There might also be stimulatory effect of magnesium on MGP in which the TRPM7 channel is involved. In conclusion there is a clear interaction between MGP and phosphate, calcium and magnesium. The upregulation of MGP by phosphate and calcium might be a cellular response that possibly results in the mitigation of VC.
75. PCV31 Clinical Characteristics, Lipid Treatment and Goal Attainment in a Familial Hypercholesterolemia Cohort in The Netherlands: a Cross Sectional Study
- Author
-
Kuiper, JG, Heintjes, EM, Houben, E, Penning-van Beest, FJ, Sanchez, RJ, Khan, I, van Riemsdijk, M, Hovingh, GK, and Herings, RM
- Full Text
- View/download PDF
76. PDB113 Intensification of Basal Insulin Treatment Among Patients With Diabetes Mellitus Type 2 In The Netherlands
- Author
-
Overbeek, J, Houben, E, Kring, S, Sommer, J, Penning-van Beest, F, van der Heijden, A, Nijpels, G, and Herings, R
- Full Text
- View/download PDF
77. PCN232 Treatment Patterns And Outcomes Of Patients Diagnosed With Ovarian Cancer In The Netherlands: A Registry Study
- Author
-
Houben, E., van Haalen, H.G.M., Sparreboom, W., Overbeek, J.A., Ezendam, N., Pijnenborg, H., and van Herk-Sukel, M.P.P.
- Full Text
- View/download PDF
78. Control measures directed at Aujeszky's disease virus: a theoretical evaluation of between-farm effects
- Author
-
Houben, E. H. P., Dijkhuizen, A. A., Jong, M. C. M. De, and Kimman, T. G.
- Published
- 1993
- Full Text
- View/download PDF
79. Federico II e la varietà delle dinamiche cittadine siciliane: alcuni esempi
- Author
-
SANTORO, Daniela, a cura di Hubert Houben e Georg Vogeler, and SANTORO, D
- Subjects
Federico II, Palermo, Messina, Catania, dinamiche cittadine, realtà locali, aspirazioni universali - Abstract
A partire dal doppio volto di Federico, re e imperatore, lo studio utilizza le fonti cronachistiche per tracciare un profilo della diversità delle dinamiche cittadine siciliane: in particolare viene indagato il rapporto tra Federico e Palermo, Messina, Catania.
- Published
- 2008
80. Il potere del segno. La transizione della Magione da baliato a commenda
- Author
-
GIUFFRIDA, Antonino, CURATORI A. GIUFFRIDA, H. HOUBEN E K. TOOMASPOEG, and GIUFFRIDA, A.
- Subjects
Ordine Teutonico, Magione, Sicilia - Published
- 2007
81. La Notitia di Antonino Amico, erudito siciliano del Seicento e l’Ordine dei Templari
- Author
-
PETRACCA, LUCIANA, HUBERT HOUBEN E BENEDETTO VETERE, and Petracca, Luciana
- Subjects
Pellegrinaggio ,Sicilia ,Antonino Amico ,Templari - Abstract
Il saggio prende in esame la "Notitia" di Antonino Amico, erudito siciliano vissuto nella prima metà del XVII secolo, sull'Ordine Templare. Attraverso la narrazione dell'Amico si è ricostruita la vicenda relativa alla nascita dell'Ordine rosso-crociato in Terrasanta e alla successiva diffusione delle "domus" siciliane.
- Published
- 2006
82. Presenze Templari in Puglia
- Author
-
PETRACCA, LUCIANA, HUBERT HOUBEN E BENEDETTO VETERE, and Petracca, Luciana
- Subjects
Pellegrinaggio ,Puglia ,Templari - Abstract
Il saggio indaga la presenza dell'Ordine Templare in Puglia.
- Published
- 2006
83. Cardiovascular risk in ANCA-associated vasculitis: Monocyte phenotyping reveals distinctive signatures between serological subsets.
- Author
-
Vegting Y, Hanford KM, Jongejan A, Gajadin GR, Versloot M, van der Bom-Baylon ND, Dekker T, Penne EL, van der Heijden JW, Houben E, Bemelman FJ, Neele AE, Moerland PD, Vogt L, Kroon J, and Hilhorst ML
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Case-Control Studies, Peroxidase blood, Immunophenotyping, Cardiovascular Diseases blood, Myeloblastin immunology, Biomarkers blood, Adult, Monocytes metabolism, Monocytes immunology, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis blood, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis immunology, Phenotype, Heart Disease Risk Factors
- Abstract
Background and Aims: Anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) is associated with an increased cardiovascular risk, particularly the myeloperoxidase AAV serotype (MPO-AAV). Distinct alterations in monocyte phenotypes may cause accelerated atherosclerotic disease in AAV., Methods: A cohort including 43 AAV patients and 19 healthy controls was included for downstream analyses. Extensive phenotyping of monocytes and monocyte-derived macrophages was performed using bulk RNA-sequencing and flow cytometry. An in vitro transendothelial migration assay reflecting intrinsic adhesive and migratory capacities of monocytes was employed. Subsequent sub-analyses were performed to investigate differences between serological subtypes., Results: Monocyte subset analysis showed increased classical monocytes during active disease, whereas non-classical monocytes were decreased compared to healthy controls (HC). RNA-sequencing revealed upregulation of distinct inflammatory pathways and lipid metabolism-related markers in monocytes of active AAV patients. No differences were detected in the intrinsic monocyte adhesion and migration capacity. Compared to proteinase-3(PR3)-AAV, monocytes of MPO-AAV patients in remission expressed genes related to inflammation, coagulation, platelet-binding and interferon signalling, whereas the expression of chemokine receptors indicative of acute inflammation and monocyte extravasation (i.e., CCR2 and CCR5) was increased in monocytes of PR3-AAV patients. During active disease, PR3-AAV was linked with elevated serum CRP and increased platelet counts compared to MPO-AAV., Conclusions: These findings highlight changes in monocyte subset composition and activation, but not in the intrinsic migration capacity of AAV monocytes. MPO-AAV monocytes are associated with sustained upregulation of inflammatory genes, whereas PR3-AAV monocytes exhibit chemokine receptor upregulation. These molecular changes may play a role in elevating cardiovascular risk as well as in the underlying pathophysiology of AAV., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
84. Added Value of 13 C Analysis in Breath Tests in H 2 -Negative Subjects to Diagnose Lactose Malabsorption: A Proof of Concept Study.
- Author
-
Balsiger LM, Houben E, Vanuytsel T, van Ranst M, Tack J, and Verbeke K
- Subjects
- Humans, Male, Female, Adult, Lactose metabolism, Lactose urine, Proof of Concept Study, Middle Aged, Case-Control Studies, Carbon Dioxide metabolism, Genotype, Young Adult, Breath Tests methods, Lactose Intolerance diagnosis, Lactose Intolerance genetics, Lactose Intolerance metabolism, Hydrogen analysis, Hydrogen metabolism, Lactase metabolism, Lactase genetics, Carbon Isotopes, Methane metabolism, Methane analysis
- Abstract
Introduction: Diagnosing lactose malabsorption is usually based on hydrogen excretion in breath after a lactose challenge. However, a proportion of subjects with lactose malabsorption will not present a rise in hydrogen. Measuring excretion of methane or stable isotope labeled
13 CO2 after ingestion of13 C-lactose has been proposed to mitigate this problem., Objective: The aim of the study was to assess the performance of measuring methane and13 CO2 in individuals with normal hydrogen excretion compared to a genetic lactase non-persistence test., Methods: Individuals referred for lactose breath testing and healthy controls were included. Participants received13 C-enriched lactose, performed breath testing, and underwent genotyping for a marker of lactase non-persistence (13910C*T). Using genotype as gold standard, the performance of measuring methane and13 CO2 excretion was assessed., Results: 151 subjects participated in the study, 50 of which presented a lactase non-persistent genotype. Of these, 72% were correctly diagnosed through hydrogen excretion of ≥ 20 ppm above baseline. In subjects with normal hydrogen excretion, cumulative13 C excretion had an area under the curve (AUC) of the receiver operating characteristics (ROC) curve of 0.852. Sensitivity was 93% and specificity was 51% for the current cutoff of 14.5%. The optimal cutoff was 12.65% (sensitivity 93%, specificity 70%). The ROC curve of peak methane had an AUC of 0.542 (sensitivity of 14%, specificity of 91% for cutoff ≥ 10 ppm)., Conclusions: In individuals with genetically demonstrated lactase non-persistence and negative hydrogen breath test, the use of13 C-lactose with measurement of13 CO2 excretion and hydrogen is a well-performing test to detect the lactose malabsorption and performs better than methane in our cohort., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)- Published
- 2024
- Full Text
- View/download PDF
85. Not Everything Is as It Seems: A Case Series and Overview of Diseases Mimicking Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
- Author
-
Houben E, de Groot PF, Vegting Y, Vos JMI, Nur E, Hilhorst ML, Hak AEL, and Kwakernaak AJ
- Abstract
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare heterogeneous disease in which treatment must be initiated early to prevent irreversible organ damage and death. There are several diseases that can mimic AAV, even in the presence of positive ANCA serology and/or histological evidence of vasculitis, as demonstrated in this case series. We reflect on the diagnostic approach of patients with AAV and provide an overview of AAV-mimicking diseases that can be considered in patients with atypical disease presentation or course.
- Published
- 2023
- Full Text
- View/download PDF
86. Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis.
- Author
-
Durán CE, Riera-Arnau J, Abtahi S, Pajouheshnia R, Hoxhaj V, Gamba M, Alsina E, Martin-Perez M, Garcia-Poza P, Llorente-Garcia A, Gonzalez-Bermejo D, Ibánez L, Sabaté M, Vidal X, Ballarín E, Sanfélix-Gimeno G, Rodríguez-Bernal C, Peiró S, García-Sempere A, Sanchez-Saez F, Ientile V, Ingrasciotta Y, Guarneri C, Tanaglia M, Tari M, Herings R, Houben E, Swart-Polinder K, Holthuis E, Huerta C, Gini R, Roberto G, Bartolini C, Paoletti O, Limoncella G, Girardi A, Hyeraci G, Andersen M, Kristiansen SB, Hallgreen CE, Klungel O, and Sturkenboom M
- Abstract
Background: In March 2018, the European pregnancy prevention programme for oral retinoids was updated as part of risk minimisation measures (RMM), emphasising their contraindication in pregnant women. Objective: To measure the impact of the 2018 revision of the RMMs in Europe by assessing the utilisation patterns of isotretinoin, alitretinoin and acitretin, contraceptive measures, pregnancy testing, discontinuation, and pregnancy occurrence concomitantly with a retinoid prescription. Methods: An interrupted time series (ITS) analysis to compare level and trend changes after the risk minimisation measures implementation was conducted on a cohort of females of childbearing age (12-55 years of age) from January 2010 to December 2020, derived from six electronic health data sources in four countries: Denmark, Netherlands, Spain, and Italy. Monthly utilisation figures (incidence rates [IR], prevalence rates [PR] and proportions) of oral retinoids were calculated, as well as discontinuation rates, contraception coverage, pregnancy testing, and rates of exposed pregnancies to oral retinoids, before and after the 2018 RMMs. Results: From 10,714,182 females of child-bearing age, 88,992 used an oral retinoid at any point during the study period (mean age 18.9-22.2 years old). We found non-significant level and trend changes in incidence or prevalence of retinoid use in females of child-bearing age after the 2018 RMMs. The reason of discontinuation was unknown in >95% of cases. Contraception use showed a significant increase trend in Spain; for other databases this information was limited. Pregnancy testing was hardly recorded thus was not possible to model ITS analyses. After the 2018 RMM, rates of pregnancy occurrence during retinoid use, and start of a retinoid during a pregnancy varied from 0.0 to 0.4, and from 0.2 to 0.8, respectively. Conclusion: This study shows a limited impact of the 2018 RMMs on oral retinoids utilisation patterns among females of child-bearing age in four European countries. Pregnancies still occur during retinoid use, and oral retinoids are still prescribed to pregnant women. Contraception and pregnancy testing information was limited in most databases. Regulators, policymakers, prescribers, and researchers must rethink implementation strategies to avoid any pregnancy becoming temporarily related to retinoid use., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Durán, Riera-Arnau, Abtahi, Pajouheshnia, Hoxhaj, Gamba, Alsina, Martin-Perez, Garcia-Poza, Llorente-Garcia, Gonzalez-Bermejo, Ibánez, Sabaté, Vidal, Ballarín, Sanfélix-Gimeno, Rodríguez-Bernal, Peiró, García-Sempere, Sanchez-Saez, Ientile, Ingrasciotta, Guarneri, Tanaglia, Tari, Herings, Houben, Swart-Polinder, Holthuis, Huerta, Gini, Roberto, Bartolini, Paoletti, Limoncella, Girardi, Hyeraci, Andersen, Kristiansen, Hallgreen, Klungel and Sturkenboom.)
- Published
- 2023
- Full Text
- View/download PDF
87. Traditional and disease-related cardiovascular risk factors in ANCA-associated vasculitis: A prospective, two-centre cohort study.
- Author
-
Vegting Y, Penne EL, Hilhorst ML, Hoekstra T, Bemelman FJ, Vogt L, Voskuyl AE, Pagnoux C, and Houben E
- Subjects
- Humans, Female, Middle Aged, Risk Factors, Cohort Studies, Prospective Studies, Heart Disease Risk Factors, Cardiovascular Diseases epidemiology, Cardiovascular Diseases etiology, Insulin Resistance, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis drug therapy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis epidemiology, Diabetes Mellitus epidemiology
- Abstract
Objectives: ANCA-associated vasculitis (AAV) has been associated with increased risk of cardiovascular (CV) events. The aim was to assess traditional and disease-related CV risk determinants in a two-centre prospective cohort of AAV patients., Methods: Patients were recruited from centres in the Netherlands and Canada. A comprehensive CV risk assessment was performed at inclusion. Subjects were followed up yearly for 3-5 years until the first CV event, death or end of follow-up. Cox proportional hazards analyses were performed to relate baseline characteristics to the first CV event., Results: A total of 144 patients were included (mean age 62 years, female sex 44%, median Framingham risk score 14.3%). Insulin resistance was present in 73% of patients tested at inclusion, independent of concurrent prednisone therapy. After a median follow-up of 2.90 years, 16 patients (11%) experienced a CV event (14 non-fatal and 2 fatal). The incidence of CV events was 5.45 per 100 patient-years. Age, Framingham risk score, HbA1c level, Diabetes Mellitus (DM), and previous CV event were significantly associated with CV events. Other factors, such as sex, impaired renal function, dyslipidemia, hypertension, smoking history and microalbuminuria, or disease-specific variables, like ANCA serotype or disease activity, were not significantly related to CV events in univariable or age-adjusted cox regression analysis., Conclusions: Determinants of an increased CV risk were identified. Disease-related factors and treatments can further modify individual risk factors, such as for steroids causing chronic insulin resistance and DM. Treatment of risk factors is essential to optimize long-term outcomes in AAV patients., (Copyright © 2023 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
88. GPs' awareness of pregnancy: trends and association with hazardous medication use.
- Author
-
Houben E, Swart KM, Steegers EA, Elders PJ, and Herings RM
- Subjects
- Humans, Female, Pregnancy, Odds Ratio, Prescriptions, Substance-Related Disorders
- Abstract
Background: GPs have been shown to be important providers of medical care during pregnancy, however, little evidence exists on their awareness of pregnancy when prescribing medication to women., Aim: To assess GPs' awareness of pregnancy and its association with prescribing medication with potential safety risks., Design and Setting: Population-based study using confirmed pregnancy records linked to GP records from the PHARMO Perinatal Research Network., Method: GPs' awareness of pregnancy, defined as the presence of a pregnancy confirmation in the GP information system during pregnancy, was assessed from 2004 to 2020. GP prescriptions of medication with potential safety risks were selected during pregnancy and its association with GPs' awareness of pregnancy was assessed using multivariable logistic regression., Results: A pregnancy confirmation was present in the GP records for 48% ( n = 67 496/140 976) of selected pregnancies, increasing from 28% ( n = 34/121) in 2004 to 63% in 2020 ( n = 5763/9124). During 3% ( n = 4489/140 976) of all pregnancies, the GP prescribed highly hazardous medication with teratogenic effects that should have been (temporarily) avoided. Pregnancy was GP confirmed for only 13% ( n = 585/4489) at the first occurrence of such a prescription. Comparative analyses showed that women without a pregnancy confirmation were 59% more likely to be prescribed this highly hazardous medication (odds ratio [OR] 1.59, 95% confidence interval [CI] = 1.49 to 1.70) compared with those with a confirmed pregnancy., Conclusion: Results of this study indicate a potential issue with GP awareness about pregnancy status at the time medication with potential safety risks is prescribed. Although pregnancy registration by GPs improved over the years, inadequate use still seems to be made of the available information systems for appropriate drug surveillance., (© The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
89. Sequential treatment with a TNFR2 agonist and a TNFR1 antagonist improves outcomes in a humanized mouse model for MS.
- Author
-
Pegoretti V, Bauer J, Fischer R, Paro I, Douwenga W, Kontermann RE, Pfizenmaier K, Houben E, Broux B, Hellings N, Baron W, Laman JD, and Eisel ULM
- Subjects
- Animals, Humans, Mice, Central Nervous System metabolism, Inflammation, Tumor Necrosis Factor-alpha metabolism, Encephalomyelitis, Autoimmune, Experimental metabolism, Multiple Sclerosis metabolism, Receptors, Tumor Necrosis Factor, Type I agonists, Receptors, Tumor Necrosis Factor, Type II agonists
- Abstract
TNF signaling is an essential regulator of cellular homeostasis. Through its two receptors TNFR1 and TNFR2, soluble versus membrane-bound TNF enable cell death or survival in a variety of cell types. TNF-TNFRs signaling orchestrates important biological functions such as inflammation, neuronal activity as well as tissue de- and regeneration. TNF-TNFRs signaling is a therapeutic target for neurodegenerative diseases such as multiple sclerosis (MS) and Alzheimer's disease (AD), but animal and clinical studies yielded conflicting findings. Here, we ask whether a sequential modulation of TNFR1 and TNFR2 signaling is beneficial in experimental autoimmune encephalomyelitis (EAE), an experimental mouse model that recapitulates inflammatory and demyelinating aspects of MS. To this end, human TNFR1 antagonist and TNFR2 agonist were administered peripherally at different stages of disease development in TNFR-humanized mice. We found that stimulating TNFR2 before onset of symptoms leads to improved response to anti-TNFR1 therapeutic treatment. This sequential treatment was more effective in decreasing paralysis symptoms and demyelination, when compared to single treatments. Interestingly, the frequency of the different immune cell subsets is unaffected by TNFR modulation. Nevertheless, treatment with only a TNFR1 antagonist increases T-cell infiltration in the central nervous system (CNS) and B-cell cuffing at the perivascular sites, whereas a TNFR2 agonist promotes Treg CNS accumulation. Our findings highlight the complicated nature of TNF signaling which requires a timely balance of selective activation and inhibition of TNFRs in order to exert therapeutic effects in the context of CNS autoimmunity., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
90. Incidence of Lyme Borreliosis in the Dutch General Practice Population: A Large-Scale Population-Based Cohort Study Across the Netherlands Between 2015 and 2019.
- Author
-
Houben E, de Jong H, Penning-van Beest F, Kuiper J, Holthuis E, Blum M, Skufca J, Riera-Montes M, Gessner BD, Pilz A, Vyse AJ, Begier E, Dzingina M, Herings R, and Stark JH
- Subjects
- Female, Animals, Incidence, Netherlands epidemiology, Cohort Studies, Lyme Disease epidemiology, Lyme Disease diagnosis, Lyme Disease veterinary, Erythema Chronicum Migrans epidemiology, Erythema Chronicum Migrans veterinary, General Practice
- Abstract
Background: There is a need for updated incidence rates (IRs) of Lyme borreliosis (LB) in Europe, including the Netherlands. We estimated LB IRs stratified by geographic area, year, age, sex, immunocompromised status, and socioeconomic status (SES). Methods: All subjects registered in the PHARMO General Practitioner (GP) Database without prior diagnosis of LB or disseminated LB and having ≥1 year of continuous database enrolment were included. IRs and corresponding confidence intervals (CIs) of GP-recorded LB, erythema migrans (EM), and disseminated LB were estimated during the period 2015‒2019. Results: We identified 14,794 events (suspected, probable, or confirmed) with a diagnostic code for LB that included 8219 with a recorded clinical manifestation: 7985 (97%) with EM and 234 (3%) with disseminated LB. National annual LB IRs were relatively consistent, ranging from 111 (95% CI 106‒115) in 2019 to 131 (95% CI 126‒136) in 2018 per 100,000 person-years. Incidence of LB showed a bimodal age distribution, with peak IRs observed among subjects aged 5‒14 and 60‒69 years in men and women. Higher LB incidence was found in subjects who were residents of the provinces of Drenthe and Overijssel, immunocompromised, or of lower SES. Similar patterns were observed for EM and disseminated LB. Conclusions: Our findings confirm that LB incidence remains substantial throughout the Netherlands with no indication of decline in the past 5 years. Foci in two provinces and among vulnerable populations suggest potential initial target groups for preventive strategies such as vaccination.
- Published
- 2023
- Full Text
- View/download PDF
91. Performance of the JF5-Based Galactomannoprotein EIA Compared to the Lateral Flow Device and the Galactomannan EIA in Serum and Bronchoalveolar Lavage Fluid.
- Author
-
Aerts R, Mercier T, Houben E, Schauwvlieghe A, Lagrou K, and Maertens J
- Subjects
- Animals, Mice, Bronchoalveolar Lavage Fluid, Sensitivity and Specificity, Mannans, Antigens, Fungal, Aspergillus, Enzyme-Linked Immunosorbent Assay, Invasive Pulmonary Aspergillosis diagnosis, Aspergillosis diagnosis, Invasive Fungal Infections
- Abstract
Early diagnosis of invasive aspergillosis is an important factor to improve survival but remains challenging. The detection of Aspergillus antigens is included in the consensus case definitions of the European Organization for Research and Treatment of Cancer and the National Institute of Allergy and Infectious Diseases Mycoses Study Group as a criterion of "probable" invasive aspergillosis. JF5, a mouse IgG3 monoclonal antibody detecting an Aspergillus mannoprotein, has already been implemented as a lateral flow device (LFD). Now, also a JF5-based enzyme-linked immunosorbent assay (EIA) is commercialized (Aspergillus specific galactomannoprotein [GP] EIA, Euroimmun Medizinische Labordiagnostika AG). In this study, we analyzed the diagnostic performance of GP in 63 bronchoalveolar lavage fluid (BALf) samples and 224 serum samples and compared it to performance of the galactomannan (GM) (Platelia Aspergillus enzyme immunoassay (EIA) (Bio-Rad, Marnes-la-Coquette, France)) and the JF5-based LFD (AspLFD; OLM Diagnostics, Newcastle Upon Tyne, United Kingdom). The diagnostic performance of GP and GM correlated well with both having high specificity. With an optimized cutoff threshold for positivity of 0.4-deviating from the 0.5 threshold recommended by the manufacturer-sensitivity of GP in serum is not significantly different than that of GM. However, in BALf sensitivity of GP is significantly less than for GM.
- Published
- 2022
- Full Text
- View/download PDF
92. Oncostatin M triggers brain inflammation by compromising blood-brain barrier integrity.
- Author
-
Hermans D, Houben E, Baeten P, Slaets H, Janssens K, Hoeks C, Hosseinkhani B, Duran G, Bormans S, Gowing E, Hoornaert C, Beckers L, Fung WK, Schroten H, Ishikawa H, Fraussen J, Thoelen R, de Vries HE, Kooij G, Zandee S, Prat A, Hellings N, and Broux B
- Subjects
- Animals, Endothelial Cells metabolism, Endothelial Cells pathology, Mice, Mice, Inbred C57BL, Multiple Sclerosis metabolism, Multiple Sclerosis pathology, Oncostatin M Receptor beta Subunit biosynthesis, Oncostatin M Receptor beta Subunit genetics, Th17 Cells metabolism, Th17 Cells pathology, Blood-Brain Barrier metabolism, Blood-Brain Barrier pathology, Encephalomyelitis, Autoimmune, Experimental genetics, Encephalomyelitis, Autoimmune, Experimental metabolism, Encephalomyelitis, Autoimmune, Experimental pathology, Oncostatin M metabolism, Oncostatin M pharmacology
- Abstract
Oncostatin M (OSM) is an IL-6 family member which exerts neuroprotective and remyelination-promoting effects after damage to the central nervous system (CNS). However, the role of OSM in neuro-inflammation is poorly understood. Here, we investigated OSM's role in pathological events important for the neuro-inflammatory disorder multiple sclerosis (MS). We show that OSM receptor (OSMRβ) expression is increased on circulating lymphocytes of MS patients, indicating their elevated responsiveness to OSM signalling. In addition, OSM production by activated myeloid cells and astrocytes is increased in MS brain lesions. In experimental autoimmune encephalomyelitis (EAE), a preclinical model of MS, OSMRβ-deficient mice exhibit milder clinical symptoms, accompanied by diminished T helper 17 (Th17) cell infiltration into the CNS and reduced BBB leakage. In vitro, OSM reduces BBB integrity by downregulating the junctional molecules claudin-5 and VE-cadherin, while promoting secretion of the Th17-attracting chemokine CCL20 by inflamed BBB-endothelial cells and reactive astrocytes. Using flow cytometric fluorescence resonance energy transfer (FRET) quantification, we found that OSM-induced endothelial CCL20 promotes activation of lymphocyte function-associated antigen 1 (LFA-1) on Th17 cells. Moreover, CCL20 enhances Th17 cell adhesion to OSM-treated inflamed endothelial cells, which is at least in part ICAM-1 mediated. Together, these data identify an OSM-CCL20 axis, in which OSM contributes significantly to BBB impairment during neuro-inflammation by inducing permeability while recruiting Th17 cells via enhanced endothelial CCL20 secretion and integrin activation. Therefore, care should be taken when considering OSM as a therapeutic agent for treatment of neuro-inflammatory diseases such as MS., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
93. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.
- Author
-
Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, Boumpas DT, Brodin N, Bruce IN, González-Gay MÁ, Jacobsen S, Kerekes G, Marchiori F, Mukhtyar C, Ramos-Casals M, Sattar N, Schreiber K, Sciascia S, Svenungsson E, Szekanecz Z, Tausche AK, Tyndall A, van Halm V, Voskuyl A, Macfarlane GJ, Ward MM, Nurmohamed MT, and Tektonidou MG
- Subjects
- Heart Disease Risk Factors, Humans, Risk Factors, Uric Acid, Antiphospholipid Syndrome complications, Antiphospholipid Syndrome drug therapy, Cardiovascular Diseases etiology, Cardiovascular Diseases prevention & control, Gout complications, Lupus Erythematosus, Systemic diagnosis, Mixed Connective Tissue Disease complications, Musculoskeletal Diseases, Myositis, Rheumatic Diseases complications, Rheumatic Diseases drug therapy, Scleroderma, Systemic complications, Sjogren's Syndrome complications, Vasculitis complications
- Abstract
Objective: To develop recommendations for cardiovascular risk (CVR) management in gout, vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD), Sjögren's syndrome (SS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS)., Methods: Following European League against Rheumatism (EULAR) standardised procedures, a multidisciplinary task force formulated recommendations for CVR prediction and management based on systematic literature reviews and expert opinion., Results: Four overarching principles emphasising the need of regular screening and management of modifiable CVR factors and patient education were endorsed. Nineteen recommendations (eleven for gout, vasculitis, SSc, MCTD, myositis, SS; eight for SLE, APS) were developed covering three topics: (1) CVR prediction tools; (2) interventions on traditional CVR factors and (3) interventions on disease-related CVR factors. Several statements relied on expert opinion because high-quality evidence was lacking. Use of generic CVR prediction tools is recommended due to lack of validated rheumatic diseases-specific tools. Diuretics should be avoided in gout and beta-blockers in SSc, and a blood pressure target <130/80 mm Hg should be considered in SLE. Lipid management should follow general population guidelines, and antiplatelet use in SLE, APS and large-vessel vasculitis should follow prior EULAR recommendations. A serum uric acid level <0.36 mmol/L (<6 mg/dL) in gout, and disease activity control and glucocorticoid dose minimisation in SLE and vasculitis, are recommended. Hydroxychloroquine is recommended in SLE because it may also reduce CVR, while no particular immunosuppressive treatment in SLE or urate-lowering therapy in gout has been associated with CVR lowering., Conclusion: These recommendations can guide clinical practice and future research for improving CVR management in rheumatic and musculoskeletal diseases., Competing Interests: Competing interests: GCD, DV, EH, LB, SB, DTB, NB, GK, FM, CM, MR-C, KS, SS, VPvH, GJM, MMW and MN have nothing to declare. FA: research grants from BMS, Celgene, Novartis and Sandoz and consulting fees from AbbVie, Biogen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer and Sanofi-Aventis, all unrelated to this manuscript; INB: grant from GSK paid to institution, consulting fees from Astra Zeneca, GSK, Eli lilly, UC, MSD paid to institution, support for attending meetings and/or travel from GSK, participation on a data safety monitoring board/or advisory board from Aurinia, Astra Zeneca and ILTOO paid to institution, all unrelated to this manuscript; MÁG-G: grants/research support from AbbVie, MSD, Jansen and Roche paid to institution and personal consulting fees/participation in company sponsored speakers bureau from AbbVie, Pfizer, Roche, Celgene, MSD, Novartis, SOBI and Sanofi, all unrelated to this manuscript; SJ: grants from BMS paid to institution, personal consulting fees from Astra Zeneca, and personal fees from Danish Medicolegal Council, all unrelated to this manuscript; NS: grants paid to institution from Astrazeneca, Boehringer Ingelheim and Roche Diagnostics, personal consulting fees from Afimmune, Amgen, Astrazeneca, Boehringer Ingelheim, Eli-Lilly, Hanmi Pharamceuticals, MSD, Novartis, Novo Nordisk, Pfizer and Sanofi, all unrelated to this manuscript; ES: grant from Merck and honoraria from Janssen, all unrelated to this manuscript; ZS: research grants from Pfizer paid to institution and personal consulting fees from Pfizer, MSD, Lilly, Novartis, Roche, Gedeon Richter, Boehringer Ingelheim, Abbvie, all unrelated to this manuscript; A-KT: speakers fee from Berlin Chemie Menarini, Novarti and personal fees and non-financial support from AstraZeneca and Grünenthal, all unrelated to this manuscript; AT: consulting fees from Magenta Therapeutics and personal fees from Novartis and Idorsia for participation on a Data Safety Monitoring Board or Advisory Board, all unrelated to this manuscript; AV: personal consulting fees from Astra Zeneca and GS, all unrelated to this manuscript; MGT: research grants from Genesis, GSK, MSD, Pfizer and UCB paid to institution, and personal consulting fees from Genesis, GSK and Novartis, all unrelated to this manuscript., (© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
94. Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany.
- Author
-
Smits E, Andreotti F, Houben E, Crijns HJGM, Haas S, Spentzouris G, Schink T, Gini R, Bartolini C, Penning-van Beest F, and Herings R
- Abstract
Background: Direct oral anticoagulants are available for patients with atrial fibrillation., Objective: This study compared adherence and persistence of once-daily (QD) vs twice-daily (BID) direct oral anticoagulants in patients with atrial fibrillation., Methods: A cohort study was conducted in three databases in the Netherlands, Italy and Germany. Patients with AF starting direct oral anticoagulants after drug approval date were included. The index date was the date of first dispensing. Study patients were restricted to those aged ≥ 18 years, ≥ 1 year database history and ≥ 1 year follow-up. Adherence to treatment was defined as the proportion of days covered ≥ 80% between the index date and the date of last dispensing of the index regimen (i.e. exposure period). The proportion of days covered was also determined during the 12-month follow-up. Persistence was defined as continuous use from index to treatment discontinuation., Results: In the Netherlands, Italy and Germany, respectively, 6068, 32,260 and 167,445 patients were included. The mean age of the patients was 70, 77 and 74 years, and 31%, 40% and 61% were QD users, all respectively. Among QD/BID users, 93/90%, 88/86% and 77/58%, respectively were adherent during the exposure period. Persistence rates at 1 year in QD/BID users were 60/59%, 13/14% and 46/31%, respectively., Conclusions: Adherence to treatment was high. In Germany, adherence was markedly higher in QD users compared with BID users. In Italy and the Netherlands, these differences were marginal. Persistence was low in all countries, but discontinuation was temporary. Only in Germany, persistence was markedly lower in BID users vs QD users., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
95. Twenty-year trends in the use of anti-seizure medication among pregnant women in the Netherlands.
- Author
-
Houben E, Benson RJ, Steegers EAP, and Herings RMC
- Subjects
- Anticonvulsants therapeutic use, Female, Humans, Netherlands epidemiology, Pregnancy, Seizures drug therapy, Seizures epidemiology, Epilepsy drug therapy, Epilepsy epidemiology, Pregnant Women
- Abstract
Background: Anti-seizure medications (ASMs) are used to treat conditions such as epilepsy and bipolar disorder. Some of these drugs are associated with an increased risk of congenital malformations and adverse developmental outcomes., Objectives: To examine trends in use of ASMs among pregnant women in the Netherlands according to medication safety profile., Methods: Using population-based data from the PHARMO Perinatal Research Network, we assessed trends in use of ASMs among pregnant women in the Netherlands between 1999 and 2019, stratified by medication safety profile. Individual treatment patterns were also assessed., Results: In total, 671,709 pregnancies among 446,169 women were selected, of which 2405 (3.6 per 1000) were ASM-exposed. Over the study period, a significant increase was observed for use of known safest ASMs (0.7-18.0 per 10,000 pregnancies) as well as for those with uncertain risk (5.3-13.4 per 10,000 pregnancies). Use of ASMs with higher risk of congenital malformations decreased significantly (24.8-14.5 per 10,000 pregnancies), except for topiramate (0-6.7 per 10,000 pregnancies). Switches between ASM safety risk categories before and during pregnancy were uncommon; women rather discontinued treatment or switched within the same category. There was no clear change for the proportion using polytherapy during pregnancy (12% overall), however a non-significant trend toward inclusion of known safest ASMs was observed over time (1.9-3.6%)., Conclusions: Over the last two decades, there has been an increase in use of known safest ASMs among pregnant women, together with a trend toward newer ASMs with uncertain risk. Only a small proportion of women switched to a safer alternative before or during pregnancy. Altogether, this highlights the need for an expansion of ASM risk knowledge and communication to healthcare providers and women of reproductive age to improve preconception counseling., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
96. Platelet aggregation inhibitor prescription for newly diagnosed peripheral arterial disease in the Netherlands: a cohort study.
- Author
-
Brand AR, Houben E, Bezemer ID, Visseren FLJ, Bots ML, Herings RM, and de Borst GJ
- Subjects
- Cohort Studies, Humans, Netherlands epidemiology, Prescriptions, Peripheral Arterial Disease drug therapy, Platelet Aggregation Inhibitors therapeutic use
- Abstract
Objectives: Pharmacological treatment of peripheral arterial disease (PAD) comprises of antiplatelet therapy (APT), blood pressure control and cholesterol optimisation. Guidelines provide class-I recommendations on the prescription, but there are little data on the actual prescription practices. Our study provides insight into the prescription of medication among patients with PAD in the Netherlands and reports a 'real-world' patient journey through primary and secondary care., Design: We conducted a cohort study among patients newly diagnosed with PAD between 2010 and 2014., Setting: Data were obtained from the PHARMO Database Network, a population-based network of electronic pharmacy, primary and secondary healthcare setting records in the Netherlands. The source population for this study comprised almost 1 million individuals., Participants: 'Newly diagnosed' was defined as a recorded International Classification of Primary Care code for PAD, a PAD-specific WCIA examination code or a diagnosis recorded as free text episode in the general practitioner records with no previous PAD diagnosis record and no prescription of P2Y12 inhibitors or aspirin the preceding year. The patient journey was defined by at least 1 year of database history and follow-up relative to the index date., Results: Between 2010 and 2014, we identified 3677 newly diagnosed patients with PAD. Most patients (91%) were diagnosed in primary care. Almost half of all patients (49%) had no APT dispensing record. Within this group, 33% received other anticoagulant therapy (vitamin K antagonist or direct oral anticoagulant). Mono-APT was dispensed as aspirin (40% of patients) or P2Y12 inhibitors (2.5% of patients). Dual APT combining aspirin with a P2Y12 inhibitor was dispensed to 8.5% of the study population., Conclusion: Half of all patients with newly diagnosed PAD are not treated conforming to (international) guideline recommendations on thromboembolism prevention through APT. At least 33% of all patients with newly diagnosed PAD do not receive any antithrombotic therapy. Evaluation and improvement of APT prescription and thereby improved prevention of (secondary) cardiovascular events is warranted., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
97. Respiratory morbidity, healthcare resource use, and cost burden associated with extremely preterm birth in The Netherlands.
- Author
-
Houben E, Siffel C, Overbeek J, Penning-van Beest F, Niklas V, and Sarda SP
- Subjects
- Delivery of Health Care, Female, Gestational Age, Humans, Infant, Infant, Extremely Premature, Infant, Newborn, Morbidity, Netherlands epidemiology, Pregnancy, Retrospective Studies, Bronchopulmonary Dysplasia epidemiology, Premature Birth epidemiology
- Abstract
Background: Extremely preterm (EP) infants have high rates of respiratory morbidity and correspondingly high healthcare resource utilization., Objectives: Data from the PHARMO Perinatal Research Network were analyzed to quantify the burden of EP birth in the Netherlands., Methods: A retrospective analysis included infants <28 weeks gestational age with a birth record in the Perinatal Registry (1999-2015) and data in the PHARMO Database Network. Outcomes of interest included select comorbidities, hospital readmissions, and costs of hospitalization and medication up to 1- and 2-years corrected age. Outcomes were stratified by birth period (1999-2005, 2000-2009, 2010-2015) and by diagnosis of bronchopulmonary dysplasia (BPD) and chronic lung disease (CLD)., Results: The cohort included 168 EP infants (37 born 1999-2005, 51 born 2006-2009, 80 born 2010-2015). Median (Q1-Q3) birth weights decreased by birth period from 970 (840-1,035) g in 1999-2005 to 853 (695-983) g in 2010-2015. Overall, BPD and CLD were reported during the birth hospitalization in 40% and 29% of infants, respectively; rates of BPD increased and rates of CLD decreased by birth period. Eighty-four percent of EP infants had an additional comorbidity. Mean (standard deviation) costs of birth hospitalization were €110,600 (€73,000) for 1999-2005, €119,350 (€60,650) for 2006-2009, and €138,800 (€130,100) for 2010-2015. Birth hospitalization and total costs for up to 1- and 2-years corrected age were higher for infants with BPD and/or CLD than for those without either complication., Conclusion: Healthcare resource utilization and costs for EP infants, especially for those with respiratory morbidities, increased between 1999 and 2015. Future cost-effectiveness analyses are essential to determine the economic impact of this change and underscore the need for new therapeutic interventions to decrease clinical sequelae in this vulnerable population.
- Published
- 2021
- Full Text
- View/download PDF
98. Dutch trends in the use of potentially harmful medication during pregnancy.
- Author
-
Houben E, Te Winkel B, Steegers EAP, and Herings RMC
- Subjects
- Canada, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Netherlands epidemiology, Pregnancy, Pregnancy Trimester, First, Ethnicity, Pharmaceutical Preparations
- Abstract
Aims: Recent population-based data on drug utilization around pregnancy are lacking. This study aims to examine the prevalence of drug exposure in the Netherlands during the preconception, pregnancy and postpartum periods, with special emphasis on trends of potentially harmful medication over the years., Methods: A population-based study was conducted using records from the PHARMO Perinatal Research Network. From 1999 to 2017, the proportion of pregnancies during which women used any medication or potentially harmful medication was assessed, overall and stratified by timing of exposure relative to pregnancy and by the year of delivery., Results: Overall, 357 226 (73%) and 166 484 (34%) of 487 122 selected pregnancies were exposed to any and potentially harmful medication, respectively. Among these 487 122 pregnancies, preconception prevalence for use of potentially harmful medication was 43%, 24% during the first trimester, 19% during the second, 16% during the third, and 45% postpartum. A declining trend was observed for exposure to any medication, from 84% in 1999 to 68% in 2017. No clear changes were observed over time for the proportion of pregnancies exposed to potentially harmful medication., Conclusions: Our study shows that the use of potentially harmful medication was high over the last two decades. Although there was a declining trend over the years in overall medication use, during a steady one-third of pregnancies, women used potentially harmful medication. Our findings highlight the need for an increased sense of urgency among both healthcare providers and women of reproductive age regarding potential risks associated with pharmacological treatment during pregnancy., (© 2020 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.)
- Published
- 2020
- Full Text
- View/download PDF
99. Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs.
- Author
-
Van Elslande J, Decru B, Jonckheere S, Van Wijngaerden E, Houben E, Vandecandelaere P, Indevuyst C, Depypere M, Desmet S, André E, Van Ranst M, Lagrou K, and Vermeersch P
- Subjects
- Adult, Aged, Aged, 80 and over, Betacoronavirus isolation & purification, COVID-19, COVID-19 Testing, Clinical Laboratory Techniques, Coronavirus Nucleocapsid Proteins, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunoassay, Immunoglobulin G blood, Male, Middle Aged, Pandemics, Phosphoproteins, Retrospective Studies, SARS-CoV-2, Sensitivity and Specificity, Seroconversion, Young Adult, Antibodies, Viral blood, Betacoronavirus immunology, Coronavirus Infections diagnosis, Nucleocapsid Proteins immunology, Pneumonia, Viral diagnosis, Spike Glycoprotein, Coronavirus immunology
- Abstract
Objectives: The aim was to determine the antibody response against SARS-CoV-2 spike protein and nucleoprotein using four automated immunoassays and three ELISAs for the detection of total Ig antibodies (Roche) or IgG (Abbott, Diasorin, Snibe, Euroimmun, Mikrogen) in COVID-19 patients., Methods: Sensitivity and dynamic trend to seropositivity were evaluated in 233 samples from 114 patients with moderate, severe or critical COVID-19 confirmed with PCR on nasopharyngeal swab. Specificity was evaluated in 113 samples collected before January 2020, including 24 samples from patients with non-SARS coronavirus infection., Results: Sensitivity for all assays was 100% (95% confidence interval 83.7-100) 3 weeks after onset of symptoms. Specificity varied between 94.7% (88.7-97.8) and 100% (96.1-100). Calculated at the cut-offs that corresponded to a specificity of 95% and 97.5%, Roche had the highest sensitivity (85.0% (79.8-89.0) and 81.1% (76.6-85.7), p < 0.05 except vs. Abbott). Seroconversion occurred on average 2 days earlier for Roche total Ig anti-N and the three IgG anti-N assays (Abbott, Mikrogen, Euroimmun) than for the two IgG anti-S assays (Diasorin, Euroimmun) (≥50% seroconversion day 9-10 vs. day 11-12 and p < 0.05 for percent seropositive patients day 9-10 to 17-18). There was no significant difference in the IgG antibody time to seroconversion between critical and non-critical patients., Discussion: Seroconversion occurred within 3 weeks after onset of symptoms with all assays and on average 2 days earlier for assays detecting IgG or total Ig anti-N than for IgG anti-S. The specificity of assays detecting anti-N was comparable to anti-S and excellent in a challenging control population., (Copyright © 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
100. Comparison of the diagnostic performance with whole blood and plasma of four rapid antibody tests for SARS-CoV-2.
- Author
-
Decru B, Van Elslande J, Weemaes M, Houben E, Empsen I, André E, Van Ranst M, Lagrou K, and Vermeersch P
- Subjects
- Adult, Antibodies, Viral blood, COVID-19, COVID-19 Testing, Clinical Laboratory Techniques trends, Coronavirus Infections blood, Coronavirus Infections diagnosis, Coronavirus Infections virology, Female, Humans, Male, Pandemics, Plasma chemistry, Pneumonia, Viral blood, Pneumonia, Viral virology, SARS-CoV-2, Sensitivity and Specificity, Betacoronavirus immunology, Clinical Laboratory Techniques methods, Coronavirus Infections immunology, Pneumonia, Viral immunology
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.